Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SD Qfitlia Coverage | OpenP…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.91

    Qfitlia® (fitusiran) Coverage for Hemophilia Prophylaxis

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.91 alerts

    Get alerted when Policy 05.05.91 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage of Qfitlia for routine prophylaxis in adults and pediatric members age 12 and older with hemophilia A or B, subject to clinical criteria, documentation requirements, prescriber qualifications, monitoring, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyQfitlia® (fitusiran) Coverage for Hemophilia Prophylaxis
    Policy CodePolicy 05.05.91
    Change TypeNo material clinical or coverage change
    Effective DateAugust 30, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with chart notes and applicable baseline laboratory documentation; continuation requests must document benefit from therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12+
    Minimum age
    <1% / ≤2%Factor VIII / IX thresholds
    1 per 28 daysQuantity limit
    15–35%Target antithrombin range

    Coverage Criteria

    Initial therapy

    Authorization of 12 months may be granted when all of the following criteria are met.

    Initial therapy criteria

    • ONE of

      • Member has hemophilia A with severe factor VIII deficiency.Factor VIII level <1%
      • Member has hemophilia B with severe factor IX deficiency.Factor IX level ≤2%
    • Member is 12 years of age or older.Age ≥12
    • Qfitlia is being used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
    • Qfitlia will not be used to treat breakthrough bleeding.
    • Member does not have a co-existing coagulation disorder other than hemophilia A or B.
    • Member does not have a history of arterial or venous thromboembolism, significant valvular disease, atrial fibrillation, or a co-existing thrombophilic disorder, such as Factor V Leiden mutation.
    • Member does not have a history of symptomatic gallbladder disease.
    • Member does not have a history of or plans to undergo immune tolerance treatment.
    • Baseline antithrombin activity is not below 60%.AT activity ≥60%
    • Baseline alanine transaminase and/or aspartate aminotransferase is not greater than 1.5 times the upper limit of normal.ALT/AST ≤1.5 times ULN
    • Member does not have clinically significant liver disease.
    • Qfitlia will not be used in combination with Alhemo, Hemlibra, or Hympavzi.
    • Member has not previously received hemophilia gene therapy, such as Beqvez, Hemgenix, or Roctavian.
    • Prophylactic bypassing agents, factor VIII products, and factor IX products will be discontinued no later than 7 days after the initial Qfitlia dose.Discontinue within 7 days of initial dose
    • The provider attests that antithrombin activity and liver enzymes will be monitored according to the protocol outlined in the prescribing information.

    Continuation therapy

    Authorization of 12 months may be granted for continued treatment when all of the following criteria are met.

    Continuation therapy criteria

    • Member is experiencing benefit from therapy, such as reduced frequency or severity of bleeding episodes.Documented clinical benefit

      Continuation requests should include chart notes documenting benefit from therapy.

    • Member is not using Qfitlia in combination with bypassing agents, factor VIII products, or factor IX products for prophylactic use.

    Qfitlia must be used for routine prophylaxis to prevent or reduce bleeding episodes and must not be used to treat breakthrough bleeding. Qfitlia must not be used in combination with Alhemo, Hemlibra, or Hympavzi, or with prophylactic bypassing agents, factor VIII products, or factor IX products. Prophylactic bypassing-agent and factor-product therapy must be discontinued no later than 7 days after the initial Qfitlia dose.

    Coverage is excluded for members with co-existing coagulation disorders other than hemophilia A or B; a history of arterial or venous thromboembolism; significant valvular disease or atrial fibrillation; or a co-existing thrombophilic disorder, such as Factor V Leiden mutation. Members with a history of symptomatic gallbladder disease, clinically significant liver disease, or prior hemophilia gene therapy are also excluded.

    Baseline laboratory findings must not include antithrombin activity below 60% or ALT and/or AST greater than 1.5 times the upper limit of normal (ULN). Members with either finding do not meet the coverage requirements.

    Members with a history of or plans to undergo immune tolerance treatment are excluded from coverage.

    Qfitlia is considered not medically necessary when the member does not meet the policy criteria. Members receiving Qfitlia through samples or a manufacturer patient assistance program must still satisfy the initial approval criteria.

    Initial Therapy Criteria

    Initial approval

    Authorization of 12 months may be granted for hemophilia A or B when all initial approval criteria are met.

    Initial approval criteria

    • ONE of

      • Member has hemophilia A with severe factor VIII deficiency.Factor VIII level <1%
      • Member has hemophilia B with severe factor IX deficiency.Factor IX level ≤2%
    • Member is 12 years of age or older.Age ≥12

    Continuation Criteria

    Continuation therapy

    Authorization of 12 months may be granted for continued treatment when all continuation criteria are met.

    Continuation criteria

    • Member is experiencing benefit from therapy, such as reduced frequency or severity of bleeding episodes.Documented benefit from treatment

      Continuation requests should include chart notes documenting benefit from therapy.

    • Member is not using Qfitlia in combination with bypassing agents, factor VIII products, or factor IX products for prophylactic use.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCSCovered
    J7174Injection, fitusiran, 0.04 mg
    Billing CodeHCPCS
    J7174Injection, fitusiran, 0.04 mg (effective 10/1/2025)
    Threshold
    Severe factor VIII deficiencyFactor VIII level less than 1%
    Threshold
    Severe factor IX deficiencyFactor IX level of 2% or less
    Baseline requirement
    Baseline antithrombin activityMust not be below 60%
    Baseline requirement

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Submission Required

    Submit the required documentation with initial and continuation prior authorization requests to initiate review.

    • For initial requests: chart notes and applicable laboratory results.
    • For continuation requests: chart notes documenting benefit from therapy.
    Prior Authorization

    Hematologist Involvement Required

    The requested medication must be prescribed by or in consultation with a hematologist.

    Documentation Required

    Initial Request Documentation

    Background

    Qfitlia (fitusiran) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric members aged 12 years and older with hemophilia A or B, including members with or without factor VIII or factor IX inhibitors. Coverage is limited to the policy’s clinical requirements, including severe factor deficiency and applicable baseline laboratory assessments.

    Definitions

    Definitions
    Severe factor VIII deficiencyFactor VIII level of less than 1%
    Definitions
    Severe factor IX deficiencyFactor IX level of 2% or less
    Definitions
    Routine prophylaxisTreatment intended to prevent or reduce bleeding episodes on a routine basis, rather than treatment of an acute breakthrough bleed

    Quantity Limits and Monitoring

    Quantity limits
    Qfitlia 20 mg/0.2 mL solution vialQuantity limit of 1 vial per 28 days
    Quantity limits
    Qfitlia 50 mg/0.5 mL solution auto-injector penQuantity limit of 1 pen per 28 days
    Monitoring schedule
    Antithrombin activity monitoringMeasure antithrombin activity at Weeks 4, 12, 20, and 24 after the starting dose and after any dose modification; once the target range is established, measure annually
    Quantity limits
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyQfitlia® (fitusiran) Coverage for Hemophilia Prophylaxis
    Policy CodePolicy 05.05.91
    Change TypeNo material clinical or coverage change
    Effective DateAugust 30, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with chart notes and applicable baseline laboratory documentation; continuation requests must document benefit from therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaCoding and Clinical ThresholdsProvider Requirements and Denial RisksBackgroundDefinitionsQuantity Limits and Monitoring
  1. Member is using Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
  2. Member will not use Qfitlia to treat breakthrough bleeding.
  3. Member does not have a co-existing coagulation disorder other than hemophilia A or B.
  4. Member does not have a history of arterial or venous thromboembolism, significant valvular disease, atrial fibrillation, or a co-existing thrombophilic disorder, such as Factor V Leiden mutation.
  5. Member does not have a history of symptomatic gallbladder disease.
  6. Member does not have a history of or plans to undergo immune tolerance treatment.
  7. Baseline antithrombin activity is not below 60%.AT activity ≥60%
  8. Baseline alanine transaminase and/or aspartate aminotransferase is not greater than 1.5 times the upper limit of normal.ALT/AST ≤1.5 times ULN
  9. Member does not have clinically significant liver disease.
  10. Member will not use Qfitlia in combination with Alhemo, Hemlibra, or Hympavzi.
  11. Member has not previously received treatment with a gene therapy product for hemophilia A or B, such as Beqvez, Hemgenix, or Roctavian.
  12. Prophylactic bypassing agents, factor VIII products, and factor IX products will be discontinued no later than 7 days after the initial Qfitlia dose.Discontinue within 7 days of initial dose
  13. The provider attests that antithrombin activity and liver enzymes will be monitored according to the protocol outlined in the prescribing information.
  14. Baseline hepatic enzymes
    ALT and/or AST must not exceed 1.5 times the upper limit of normal (ULN)
    Dosing target
    Target antithrombin activity15–35%
    Dose adjustment
    Antithrombin activity below targetIf antithrombin activity is less than 15%, a dose reduction is required
    Dose adjustment
    Antithrombin activity above targetIf antithrombin activity is greater than 35% after 6 months, or satisfactory bleed control has not been achieved, dose escalation should be considered

    For an initial request, provide chart notes and laboratory results documenting the member's severe factor deficiency, baseline antithrombin activity, and baseline hepatic assessments, where applicable.

    • Severe factor VIII deficiency: factor VIII level <1%.
    • Severe factor IX deficiency: factor IX level ≤2%.
    • Baseline antithrombin (AT) activity.
    • Baseline hepatic assessments.
    Documentation Required

    Continuation Documentation

    For continuation requests, submit chart notes demonstrating benefit from therapy, such as reduced frequency or severity of bleeding episodes.

    Prior Authorization

    Monitoring Attestation Required

    The provider must attest that antithrombin activity and liver enzymes will be monitored according to the protocol outlined in the prescribing information.

    • Monitor antithrombin (AT) activity.
    • Monitor liver enzymes.
    Denial Risk

    Criteria Not Met: Not Medically Necessary

    Qfitlia is not medically necessary when the member does not meet the applicable coverage criteria. Members currently receiving Qfitlia as samples or through the manufacturer's patient assistance program must meet the initial approval criteria.

    • Sample or manufacturer-provided product does not bypass the initial approval requirements.
    • The requirement applies regardless of the provider's ability to access medication samples.
    Denial Risk

    Do Not Use for Breakthrough Bleeding

    Qfitlia must be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes and must not be used to treat breakthrough bleeding.

    • Use for breakthrough bleeding may result in denial.
    Denial Risk

    Disqualifying Comorbidities or Laboratory Findings

    Coverage may be denied when disqualifying comorbidities or laboratory findings are present.

    • Co-existing coagulation disorders other than hemophilia A or B.
    • History of arterial or venous thromboembolism, significant valvular disease, atrial fibrillation, or a co-existing thrombophilic disorder such as Factor V Leiden mutation.
    • History of symptomatic gallbladder disease or clinically significant liver disease.
    • Baseline antithrombin activity <60%.
    • Baseline ALT and/or AST >1.5 times the upper limit of normal (ULN).
    Denial Risk

    Prohibited Concurrent Therapy

    Qfitlia must not be used in combination with specified products, and prophylactic use of bypassing agents and factor products must be discontinued no later than 7 days after the initial Qfitlia dose.

    • Do not use in combination with Alhemo, Hemlibra, or Hympavzi.
    • Discontinue prophylactic bypassing agents, factor VIII products, and factor IX products no later than 7 days after the initial dose.
    • Examples of factor VIII products: Advate, Adynovate, and Eloctate.
    • Examples of factor IX products: Alprolix, Ixinity, and Rebinyn.
    Denial Risk

    Prior Gene Therapy or Immune Tolerance Treatment

    Coverage may be denied for members with prior gene therapy for hemophilia A or B or a history of, or plan to undergo, immune tolerance treatment.

    • Gene therapy examples include Beqvez, Hemgenix, and Roctavian.
    • The member must not have a history of or be planning to undergo immune tolerance treatment.
    Denial Risk

    Continuation Criteria Must Be Met

    Reauthorization for continued treatment may be granted for 12 months only when the member is experiencing benefit from therapy and is not using Qfitlia with prohibited prophylactic therapies.

    • Document benefit, such as reduced frequency or severity of bleeds.
    • The member must not use Qfitlia in combination with bypassing agents, factor VIII products, or factor IX products for prophylactic use.
    Qfitlia quantity limitsQuantity limits apply